News | June 08, 2009

Frost & Sullivan Says There is Momentum for Catheter AF Ablation Technologies

June 8, 2009 – A recent Frost & Sullivan end-user survey shows increased awareness and utilization of new tools and approaches to treating atrial fibrillation (Afib).

Market estimates show that less than 20 percent of the addressable market for atrial fibrillation therapy is being served due to limited regulatory approval and lack of provider training and expertise. The market that participants like to call "two years away, for the past ten years," is now building momentum due to ongoing clinical research and recent FDA approval of the first catheter ablation system for treatment of atrial fibrillation in February of 2009.

The latest end-user study from Frost & Sullivan's Medical Device group assesses a variety of critical dynamics of catheter ablation approaches and technologies in treatment of both paroxysmal and long-standing persistent atrial fibrillation. Electrophysiologists, cardiologists, and cardiac surgeons provided insight on factors such as adoption drivers, clinical preferences, expected impact of the economy, referral patterns, assistive technologies and brand perceptions.

Select findings include the following:

• Compared to results collected during Frost & Sullivan's 2007 End User Perceptions of Atrial Fibrillation Study, this more recent study noted a statistically significant increase in awareness of the latest trends in EP ablation procedures and technologies.

• One-quarter of electrophysiologists currently use robotic-assisted magnetic navigation systems. Of those who do not, 41 percent report that they are very unlikely to adopt a robotic or magnetic system for ablation in the next 12 months.

• Upgrading of existing products and technologies is foreseen to be very or somewhat negatively impacted by the economy by 53 percent of responding electrophysiologists.

• The most utilized ablation strategy for paroxysmal atrial fibrillation is wide-area circumferential ablation. The least utilized ablation strategy is the target-fractionated electrogram.

• On average, cardiologists on average estimate that 35 percent of their patients are aware of and receptive to ablation procedures.

Researchers conducted fieldwork in March 2009. The total sample consisted of 166 clinicians, broken down into 103 electrophysiologists, 47 general cardiologists, and 16 cardiac surgeons within the U.S.

"The atrial fibrillation market is considered to be one of the next major opportunities for growth in the cardiovascular space, particularly for companies focused on management and treatment of cardiac rhythm disorders," notes Frost & Sullivan Industry Manager Venkat Rajan. "Due to mounting clinical support and the concurrent maturation of assistive technologies that enable for more accurate target identification and treatment planning, the market is poised to undergo a significant change over the next five years.

"As the market continues to develop, there are number of key clinical and product features that system developers must define themselves around as they seek distinction in the marketplace," explains Rajan.

For more information: www.medicaldevices.frost.com

Related Content

Feature | October 15, 2014
Imricor Medical Systems, Inc. announced the first three cardiac ablation procedures were completed in the first...
Technology | March 22, 2011
March 22, 2011 - Further enhancing its cardiovascular reporting capabilities, Fujifilm Medical Systems Inc. added its...
News | November 08, 2010
November 8, 2010 – Physicians are significantly less comfortable discussing withdrawal of pacemaker (PM) and...
Feature | August 20, 2010
August 19, 2010 – Researchers at the University of Maryland School of Medicine in Baltimore have developed a novel 3-D...
News | March 31, 2010
March 31, 2010 - The number of magnetic resonance imaging (MRI) scans performed increases each year, as does the number...
News | September 08, 2009
September 8, 2009 – Siemens Healthcare and SurgiVision Inc. today announced an agreement for the codevelopment and...
News | June 19, 2009
June 19, 2009 – Medtronic Inc. today said it received CE (Conformité Européenne) mark for the company's second-...
News | September 14, 2008
September 15, 2008 - BSD Medical Corp.
News | September 08, 2008
September 8, 2008 - A new medtech spin-off from CSA Medical Inc. is reportedly about to give cancer patients and their...
News | February 10, 2008
February 11, 2008 - The American College of Cardiology will hold its Annual Scientific Session from March 29-April 1
Overlay Init